Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

IkB Peptid

Wirt: Synthetic Sodium azide
Rockland
Produktnummer ABIN964103
Hersteller Produkt- Nr.: 100-4186p

Kurzübersicht für IkB Peptid (ABIN964103)

Target

IkB

Quelle

Synthetic
  • Protein-Typ

    Synthetic

    Hersteller Produkt- Nr.

    100-4186p

    Hersteller

    Rockland

    Verwendungszweck

    IKBß Peptide

    Produktmerkmale

    NF-kappa-B inhibitor beta peptide, NF-kappa-BIB, I-kappa-B-beta, Thyroid receptor-interacting protein 9, TRIP-9, IkB-B, control peptide, blocking peptide

    Aufreinigung

    Greater than 95% specific peptide

    Reinheit

    Greater than 95% specific peptide

    Sterilität

    Sterile filtered
  • Applikationshinweise

    Application Note: Control peptide should be used at 1.0 μg per 1.0 μL of antiserum in per assay.

    Other: Control peptide should be used at 1.0 μg per 1.0 μL of antiserum per assay. 

    Beschränkungen

    Nur für Forschungszwecke einsetzbar
  • Format

    Liquid

    Konzentration

    1.0 mg/mL

    Buffer

    Buffer: None

    Stabilizer: None

    Preservative: 0.01 % (w/v) Sodium Azide

    Konservierungsmittel

    Sodium azide

    Vorsichtsmaßnahmen

    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    Lagerung

    4 °C,-20 °C

    Informationen zur Lagerung

    Store vial at -20° C prior to opening. Aliquot contents and freeze at -20° C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.

    Haltbarkeit

    6 months
  • Target

    IkB

    Hintergrund

    Synonyms: NF-kappa-B inhibitor beta peptide, NF-kappa-BIB, I-kappa-B-beta, Thyroid receptor-interacting protein 9, TRIP-9, IkB-B, control peptide, blocking peptide

    Background: Control peptide for use in control assays with purified antibody Anti-IKBB (p/n 100-4186). NFkB was originally identified as a factor that binds to the immunoglobulin kappa light chain enhancer in B cells. It was subsequently found in non-B cells in an inactive cytoplasmic form consisting of NFkB bound to IkB. NFkB was originally identified as a heterodimeric DNA binding protein complex consisting of p65 (RelA) and p50 (NFKB1) subunits. Other identified subunits include p52 (NFKB2), c-Rel, and RelB. The p65, cRel, and RelB subunits are responsible for transactivation. The p50 and p52 subunits possess DNA binding activity but limited ability to transactivate. p52 has been reported to form transcriptionally active heterodimers with the NFkB subunit p65, similar to p50/p65 heterodimers. The heterodimers of p52/p65 and p50/p65 are regulated by physical inactivation in the cytoplasm by IkB-a. IkB-a binds to the p65 subunit, preventing nuclear localization and DNA binding. Low levels of p52 and p50 homodimers can also exist in cells.

Sie sind hier:
Chat with us!